Heron Therapeutics Executive Vice President, Drug Development Kimberly Manhard's 2022 pay falls 22% to $1.4M
Heron Therapeutics reports 2022 executive compensation
By ExecPay News
Published: May 1, 2023
Heron Therapeutics reported fiscal year 2022 executive compensation information on May 1, 2023.
In 2022, three executives at Heron Therapeutics received on average a compensation package of $1.3M, a 43% decrease compared to previous year.
Average pay of disclosed executives at Heron Therapeutics
Kimberly Manhard, Executive Vice President, Drug Development, received $1.4M in total, which decreased by 22% compared to 2021. 38% of Manhard's compensation, or $546K, was in salary. Manhard also received $205K in non-equity incentive plan, $235K in option awards, $441K in stock awards, as well as $20K in other compensation.
David Szekeres, Executive Vice President, Chief Commercial Officer, received a compensation package of $1.4M, which decreased by 22% compared to previous year. 37% of the compensation package, or $533K, was in salary.
Barry D. Quart, Chief Executive Officer, earned $1.1M in 2022, a 79% decrease compared to previous year.
Related executives
You may also like
Source: SEC filing on May 1, 2023.